Immatics NV
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more
Immatics NV (IMTX) - Net Assets
Latest net assets as of December 2025: $483.89 Million USD
Based on the latest financial reports, Immatics NV (IMTX) has net assets worth $483.89 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($562.10 Million) and total liabilities ($78.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $483.89 Million |
| % of Total Assets | 86.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1910.94% |
| 10-Year Change | N/A |
| Growth Volatility | 316.87 |
Immatics NV - Net Assets Trend (2018–2025)
This chart illustrates how Immatics NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Immatics NV (2018–2025)
The table below shows the annual net assets of Immatics NV from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $483.89 Million | -15.82% |
| 2024-12-31 | $574.84 Million | +155.39% |
| 2023-12-31 | $225.08 Million | +5.59% |
| 2022-12-31 | $213.16 Million | +785.86% |
| 2021-12-31 | $24.06 Million | -76.92% |
| 2020-12-31 | $104.26 Million | +355.31% |
| 2019-12-31 | $-40.84 Million | -345.26% |
| 2018-12-31 | $-9.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immatics NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58403044200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.34 Million | 0.28% |
| Other Comprehensive Income | $-8.59 Million | -1.77% |
| Other Components | $1.28 Billion | 263.86% |
| Total Equity | $483.89 Million | 100.00% |
Immatics NV Competitors by Market Cap
The table below lists competitors of Immatics NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cyfrowy Polsat S.A
OTCGREY:CYFWF
|
$640.25 Million |
|
Kestra Medical Technologies, Ltd. Common Stock
NASDAQ:KMTS
|
$640.27 Million |
|
ABCELLERA BIOLOGICS
F:8QQ
|
$640.32 Million |
|
Biotest Aktiengesellschaft
PINK:BIESF
|
$640.35 Million |
|
Edifier Technology Co Ltd
SHE:002351
|
$639.57 Million |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
$639.55 Million |
|
ARIZONA SONORAN COPPER
F:H6F
|
$639.34 Million |
|
Gansu Qilianshan Cement Group Co Ltd
SHG:600720
|
$639.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immatics NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 574,842,000 to 483,892,964, a change of -90,949,036 (-15.8%).
- Net loss of 188,693,765 reduced equity.
- Other comprehensive income decreased equity by 9,619,342.
- Other factors increased equity by 107,364,071.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-188.69 Million | -38.99% |
| Other Comprehensive Income | $-9.62 Million | -1.99% |
| Other Changes | $107.36 Million | +22.19% |
| Total Change | $- | -15.82% |
Book Value vs Market Value Analysis
This analysis compares Immatics NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.17 | $9.68 | x |
| 2019-12-31 | $-0.67 | $9.68 | x |
| 2020-12-31 | $2.17 | $9.68 | x |
| 2021-12-31 | $0.38 | $9.68 | x |
| 2022-12-31 | $3.10 | $9.68 | x |
| 2023-12-31 | $2.79 | $9.68 | x |
| 2024-12-31 | $5.38 | $9.68 | x |
| 2025-12-31 | $3.96 | $9.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immatics NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -407.01%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.16x
- Recent ROE (-38.99%) is above the historical average (-84.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -834.06% | 0.06x | 0.00x | $-30.40 Million |
| 2019 | 0.00% | -172.05% | 0.14x | 0.00x | $-27.56 Million |
| 2020 | -219.99% | -733.84% | 0.12x | 2.44x | $-239.77 Million |
| 2021 | -395.05% | -273.45% | 0.20x | 7.26x | $-97.47 Million |
| 2022 | 17.60% | 21.71% | 0.42x | 1.91x | $16.20 Million |
| 2023 | -43.09% | -179.63% | 0.11x | 2.27x | $-119.50 Million |
| 2024 | 2.65% | 9.77% | 0.22x | 1.21x | $-42.27 Million |
| 2025 | -38.99% | -407.01% | 0.08x | 1.16x | $-237.08 Million |
Industry Comparison
This section compares Immatics NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immatics NV (IMTX) | $483.89 Million | 0.00% | 0.16x | $639.97 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |